Drug Hunter

JUNE 25, 2023

Maze’s Oral GYS1 Inhibitor, MZE001 Sanofi is paying $150 million plus up to $600 million in milestones for Maze Therapeutics’ glycogen synthase 1 (GYS1) program, including MZE001, which aims to reduce glycogen substrate build-up in Pompe disease.

Targeted Protein Degradation 130

Targeted Protein Degradation Computational Chemistry Trials Licensing 130

Sygnature Discovery

JULY 31, 2023

Founded in 2011, NuChem Sciences delivers expert integrated and standalone discovery solutions across medicinal, synthetic, scale-up, process and computational chemistry, as well as DMPK, in vitro biology and in vivo pharmacology. Previous acquisitions made were Peak Proteins in April 2022 and SB Drug Discovery in January 2023.

Computational Chemistry 52

Computational Chemistry Science Clinical Trials Pharmaceutical Companies 52

Drug Target Review

SEPTEMBER 20, 2023

Matthew subsequently put his computational chemistry skills to use in the defence sector. Following a second stint in defence, he joined Cresset in 2022, working to develop, source and evaluate new computational techniques for Cresset’s software.

Drugs 105

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals 105

LifeSciVC

APRIL 27, 2023

The premise at the time was that putting computational chemistry in the primary position for new molecule ideation would upend the drug discovery paradigm. set up a “virtual project team,” leverage Schrödinger scientists to lead computational chemistry, and do all the wet work at CROs. It did just that.

Small Molecule 40

Small Molecule Computational Chemistry Engineering Clinical Development 40